Awareness and Knowledge of Pharmacists toward Biosimilar Medicines: A Survey in Jordan
Authors:
Open Access
- 1 January 2022
- journal article
- research article
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2022 (1) , 8080308
Abstract
Aims. Pharmacists in all clinical settings are recognized drug experts and integral educators of biosimilar medicines. Therefore, the objective of this study was to assess pharmacists’ knowledge, predictors of knowledge, and views toward biosimilar medicines in Jordan. Methods. A cross‐sectional study was conducted in Jordan during October–December 2020. An Internet‐based self‐administrated questionnaire on knowledge and views was distributed using social media groups to the pharmacists among different areas in Jordan. A descriptive and univariate analysis was performed. Binary logistic regression was conducted to determine the predictors of knowledge including all variables with p < 0.20 on univariate analysis. Results. A total 536 responses were received, 502 of which were completed (93.7% response rate). A total of 52.6% of the pharmacists were knowledgeable about biosimilar medicines and the mean of knowledge level was 6.47 ± 1.62 (range 2–10). Multivariate analysis identified that respondents who had heard about biosimilars before (OR = 1.942, 95% CI = 1.231–3.063, p < 0.05) was more likely to be knowledgeable. Respondents who had not taken the course or the postgraduating training course about biosimilars that were less likely to be knowledgeable (OR = 0.548, 95% CI = 0.357–0.839, p < 0.05). A positive response was noted in pharmacist’s view regarding the implementation of biosimilar medicines in healthcare setting, biosimilar medicine prescription related to decreased costs, self‐study about biosimilar medicine, and incorporating biosimilar education program at the pharmacy school curriculum universities level. Conclusions. Pharmacists’ views and knowledge vary regarding the particularities and key issues on biosimilar medicines in Jordan. Incorporating biosimilar course in pharmacy school curriculum could improve their acceptance for future pharmacy jobs.Keywords
This publication has 52 references indexed in Scilit:
- Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?The European Journal of Health Economics, 2013
- Biosimilars: Implications for health-system pharmacistsAmerican Journal of Health-System Pharmacy, 2013
- Introduction of an Infliximab Biosimilar (CT-P13): A Five-Year Budget Impact Analysis for the Treatment of Rheumatoid Arthritis in IrelandValue in Health, 2013
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals of the Rheumatic Diseases, 2013
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnnals of the Rheumatic Diseases, 2013
- Pharmacovigilance and biosimilars: considerations, needs and challengesExpert Opinion on Biological Therapy, 2013
- The US Approach to BiosimilarsBioDrugs, 2012
- The US Approach to BiosimilarsBioDrugs, 2012
- What do prescribers think of biosimilars?Targeted Oncology, 2012
- Concept of biosimilar products in JordanBiologicals, 2011